You are here

  • Home
  • Archive
  • Volume 9, Issue 1
  • Clinician prescription of lipid-lowering drugs and achievement of treatment goals in patients with newly diagnosed type 2 diabetes mellitus

Article info

Article menu

Download PDFPDF

XML
Epidemiology/Health services research
Clinician prescription of lipid-lowering drugs and achievement of treatment goals in patients with newly diagnosed type 2 diabetes mellitus

Authors

  • Ana Cristina García-Ulloa Centro de Atención Integral del Paciente con Diabetes (CAIPaDi), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MexicoDepartment of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico PubMed articlesGoogle scholar articles
  • Claudia Lechuga-Fonseca Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico PubMed articlesGoogle scholar articles
  • Fabiola Mabel Del Razo-Olvera Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico PubMed articlesGoogle scholar articles
  • Carlos Alberto Aguilar-Salinas Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MexicoTecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, MexicoDirección de Nutrición, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico PubMed articlesGoogle scholar articles
  • Karla Ivette Galaviz Rollins School of Public Health, Emory University, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • K M Venkat Narayan Rollins School of Public Health, Emory University, Atlanta, Georgia, USA PubMed articlesGoogle scholar articles
  • Sergio Hernández-Jiménez Centro de Atención Integral del Paciente con Diabetes (CAIPaDi), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MexicoDepartment of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico PubMed articlesGoogle scholar articles
  • On behalf of Group of Study CAIPaDi
    Google scholar articles
  1. Correspondence to Dr Sergio Hernández-Jiménez; sergio.hernandezj{at}incmnsz.mx
View Full Text

Citation

García-Ulloa AC, Lechuga-Fonseca C, Del Razo-Olvera FM On behalf of Group of Study CAIPaDi, et al
Clinician prescription of lipid-lowering drugs and achievement of treatment goals in patients with newly diagnosed type 2 diabetes mellitus
BMJ Open Diabetes Research and Care 2021;9:e001891. doi: 10.1136/bmjdrc-2020-001891

Publication history

  • Received November 23, 2020
  • Revised December 24, 2020
  • Accepted December 30, 2020
  • First published February 10, 2021.
Online issue publication 
January 24, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.